T Cell Based Immunotherapy: A Deeper Dive


We would like to thank all the speakers, Attendees and sponsors who made this an exceptional event

We hope to see you back in 2019!


DAY 1:
Basic T Cell Biology and Function

 Friday, June 10th, 2016

Session 1: Basic T Cell Biology
Steve Hedrick, UCSD "CD8 T cell response to persistent viral infection" 1:00-1:40
David Masopust, U of Minnesota "Resident Memory T Cells: Quantity, Location, & Function" 1:40-2:20
Doug Green, St Judes, Memphis "Metabolic Maintenance of Asymmetric T cell Division" 2:20-3:00
Charlie Surh, Institute for Basic Science, Korea, "Cellular Mechanisms of Treg Suppression" 3:00-3:40

Session 2: T Cell Function in Tumor-Bearing Hosts
Steve Ziegler
, Benaroya Institute, Seattle "Immune regulation of tumor progression" 4:00-4:40
Thomas Duhen, AgonOx, Inc, "A Deeper Dive into Human CD4 Tumor Infiltrating Lymphocytes" 4:40-5:20
Pam Ohashi, U of Toronto, "Novel Subsets in T cell Anti-Tumor Immunity" 5:20-6:00
Lanny Kirsch - Immunosequencing in the Service of T-cell Diseases and T-cell Therapeutics" 6:00-6:40

DAY 2:
Preclinical Cancer Immunotherapy

Saturday, June 11th, 2016

Session 1: Tumor-Specific T Cell Response
Bob Schreiber, Washington University, St Louis "Personalizing Cancer Immunotherapy" 1:00-1:40
Brad Nelson, U of British Columbia, Victoria "How does the tumor genome shape the immune response to cancer?" 1:40-2:20
Andy Weinberg, Providence Cancer Center, Oregon" A Deeper Dive into Human CD4 and CD8 TIL Phenotype and Clonality" 2:20-3:00
Bernie Fox, Providence Cancer Center, Oregon "Impersonalization of Cancer: Development of a Universal Cancer Vaccine" 3:00-3:40

Session 2: Immune Therapeutic Pathways
Lieping Chen, Yale "PD-1H Pathway" 4:00-4:40
Carl Ware, Burnham Institute, San Diego "The LIGHT HVEM Network in anti Tumor Responses" 4:40-5:20
Samir Khleif, Georgia Reagents University "PI3K Pathway in T Cell Regulation" 5:20-6:00
Mark Smyth, QIMR Berghofer Medical Research Institute, "Superior Power of Neoadjuvant Immunotherapy to Eradicate Metastatic Disease" 6:00-6:40


DAY 3:
Clinical Immunotherapy

Sunday, June 12th, 2016

Session 1: Treating Cancer Patients with Immunotherapy
Mario Sznol, Yale "Clinical Development of Checkpoint Inhibitors in Melanoma" 
Edward Garon, UCLA "Checkpoint Intuition in Lung Cancer - Immunotherapy Meets the Masses" 
Rom Leidner, Providence Cancer Center "The Promise of Immunotherapy in Head and Neck Cancer" 
Carl June, U of Penn, Philadelphia "Adoptive T cell Therapy for Cancer" 

Session 2: Investigating Clinical Immunotherapy Samples
Brendan Curti, Providence Cancer Center, Oregon "Clinical Development of OX40 Agonists
Tom Gajewski, U of Chicago "T cell-inflamed tumor microenvironment and response to immunotherapy" 
Paul Tumeh, UCLA "Spatial Immune Profiling of the Cancer Microenvironment" 
Lisa Butterfield, University of Pittsburgh "T Cell responses to shared tumor antigens in cancer patients" 


With thanks to our sponsors: 


Organized by AgonOx, Inc. and The University of Hawaii Cancer Center with support by an educational grant from Celgene Corporation.